Thalidomide maintenance has unresolved issues regarding dosage and toxicity. We evaluated this in five dose cohorts in 100 patients. At a median follow-up of 32.3 months, 23 patients had stopped thalidomide for disease progression, 54 for side effects. 3-year overall and progression-free survival was 76% and 41% respectively. Dosage did not influence disease outcome but greatly affected toxicity. Fifteen patients converted from partial remission to complete remission on thalidomide at a median of 13.5 months. Maintenance doses >200 mg were largely unachievable and peripheral neuropathy was the main toxicity. Lower doses enabled more patients to stay on the drug for a useful period of time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2141.2007.06817.x | DOI Listing |
EJHaem
December 2024
Johnson & Johnson Innovative Medicine Lisbon Portugal.
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period.
Methods: A retrospective cohort multicenter study using secondary data of national hospital drug consumption database from 11 Portuguese public hospitals between 2017 and 2022.
Results: Number of MM-treated patients increased 53% over 5 years (from 825 to 1266 patients).
J Assoc Genet Technol
January 2024
Robert Larner, MD, College of Medicine, University of Vermont, Burlington, VT.
Lenalidomide, a derivative of thalidomide, is a type of immunomodulatory drug (IMiD) that has been standard therapy for multiple myeloma (MM) and other hematologic malignancies for almost two decades. The success of these drugs in MM has contributed to increased survival of patients and, as a result, patients are at risk for a secondary primary malignancy (SPM), some of which occur as a result of treatment for MM. MM patients have an increased risk for acute myeloid leukemia (AML) and Kaposi sarcoma.
View Article and Find Full Text PDFTher Clin Risk Manag
November 2024
Department of Eugenics and Genetics, Guilin People's Hospital, Guilin, Guangxi Zhuang Autonomous Region, 541002, People's Republic of China.
Objective: In this study, we evaluated the effectiveness and safety of thalidomide by clinically observing 48 individuals with β-thalassemia who have been administered thalidomide in small and medium doses over a period of two years.
Methods: Thalidomide's efficacy was gauged by tracking hemoglobin (Hb) level alterations post its administration. Liver and kidney function impact was measured through tests for alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine.
J Transl Med
November 2024
Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Background: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progression of disease are still observed within a short time after treatment. Long-term pomalidomide therapy, which potentiates T-cell functionality, might enhance the efficacy of BCMA CAR T-cell therapy.
Methods: We performed a single-center retrospective clinical study.
AME Case Rep
September 2024
Hemato-oncologic specialties center (CEDEHO), Spanish Hospital of Mexico, Mexico City, Mexico.
Background: Multiple myeloma (MM) relapse in the central nervous system (CNS) confers an adverse prognosis, usually occurring in a short period after stem cell transplant and with a short overall survival. Isolated CNS relapse is so rare that there is no current standard treatment.
Case Description: We present a 59-year-old male with an isolated CNS MM relapse, who had received autologous stem-cell transplant (ASCT) and thalidomide maintenance 11 years prior.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!